Keywords: FDA, Merz, eomin, ervical dystonia, Belpharospasm, Sagent, Imitrex, Zemuran, Strides Arcolab,

FDA OKs Merz' Xeomin for cervical dystonia and blepharospasm; and two generics for Sagent

Article | 03 August 2010

Print This

The US Food and Drug Administration has approved German drugmaker Merz’ Xeomin (incobotulinumtoxin A), a botulinum toxin type A for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in